KCL Capital’s Lucid Diagnostics LUCD Stock Holding History

KCL Capital’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$54K	–	58
2021 Q4	$54K	Buy	+10,000	New	+$81.2K	0.01%	57

Other funds holding LUCD

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

KCL Capital's LUCD Position: Q1 2022 in Review

KCL Capital sold out of Lucid Diagnostics (LUCD) in Q1 2022, closing a stake of 10,000 shares — an estimated $54K sold.

KCL Capital first reported a position in LUCD in Q4 2021 and held it in 1 quarter. The position peaked at $54K in Q4 2021. 32 funds tracked by Wall St. Rank hold LUCD as of Q1 2022.

KCL Capital reported no remaining Lucid Diagnostics position as of Q1 2022 after selling out during the quarter.
KCL Capital sold 10,000 Lucid Diagnostics shares in Q1 2022, an estimated $54K.
KCL Capital first reported a position in Lucid Diagnostics in Q4 2021 and held it in 1 quarter.
KCL Capital's Lucid Diagnostics position peaked at $54K in Q4 2021.
32 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2022.

Based on KCL Capital's 13F filing for Q1 2022, filed 16 May 2022.